NLS Pharmaceutics acquires global license for novel orexin agonist platform from Aexon Labs, targeting narcolepsy, hypersomnia, and neurodegenerative disorders.

NLS Pharmaceutics secures exclusive global license for next-generation non-sulfonamide dual orexin agonist platform from Aexon Labs, Inc. The license allows NLS to develop and commercialize novel compounds targeting orexin-1 and orexin-2 receptors, offering potential treatments for narcolepsy, hypersomnia, and neurodegenerative disorders. The compounds address various pathways in neuropharmacological therapies and have the potential to be first-in-class treatments.